XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma (EXPLORING)
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma, a Randomized, Controlled, Multicenter Clinical Trial
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A PHASE2 clinical study on Carcinoma and Digestive System Diseases, this trial is actively recruiting participants. The trial is conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and has accumulated 4 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Dec 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Mar 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- The First Affiliated Hospital with Nanjing Medical University
For direct contact, visit the study record on ClinicalTrials.gov .